TY - JOUR
T1 - Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation
AU - Lin, C. S.
AU - Pan, C. H.
PY - 2008/5
Y1 - 2008/5
N2 - Electrical, contractile and structural remodeling have been characterized in atrial fibrillation (AF), and the latter is considered to be the major contributor to AF persistence. Recent data show that interstitial fibrosis can predispose to atrial conduction impairment and AF induction. The interplay between cardiac matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitors of MMPs (TIMPs), is thought to be critical in atrial extracellular matrix (ECM) metabolism. At the molecular level, angiotensin II, transforming growth factor-β1, inflammation and oxidative stress are particularly important for ECM dysregulation and atrial fibrotic remodeling in AF. Therefore, we review recent advances in the understanding of the atrial fibrotic process, the major downstream components in this remodeling process, and the expression and regulation of MMPs and TIMPs. We also describe the activation of bioactive molecules in both clinical studies and animal models to modulate MMPs and TIMPs and their effects on atrial fibrosis in AF.
AB - Electrical, contractile and structural remodeling have been characterized in atrial fibrillation (AF), and the latter is considered to be the major contributor to AF persistence. Recent data show that interstitial fibrosis can predispose to atrial conduction impairment and AF induction. The interplay between cardiac matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitors of MMPs (TIMPs), is thought to be critical in atrial extracellular matrix (ECM) metabolism. At the molecular level, angiotensin II, transforming growth factor-β1, inflammation and oxidative stress are particularly important for ECM dysregulation and atrial fibrotic remodeling in AF. Therefore, we review recent advances in the understanding of the atrial fibrotic process, the major downstream components in this remodeling process, and the expression and regulation of MMPs and TIMPs. We also describe the activation of bioactive molecules in both clinical studies and animal models to modulate MMPs and TIMPs and their effects on atrial fibrosis in AF.
KW - Angiotensin II
KW - Atrial fibrillation
KW - Atrial remodeling
KW - Inflammation
KW - Matrix metalloproteinases
KW - Oxidative stress
KW - Tissue inhibitors of matrix metalloproteinases
KW - Transforming growth factor-β1
UR - http://www.scopus.com/inward/record.url?scp=44449120187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44449120187&partnerID=8YFLogxK
U2 - 10.1007/s00018-008-7408-8
DO - 10.1007/s00018-008-7408-8
M3 - Review article
C2 - 18322650
AN - SCOPUS:44449120187
SN - 1420-682X
VL - 65
SP - 1489
EP - 1508
JO - Cellular and Molecular Life Sciences
JF - Cellular and Molecular Life Sciences
IS - 10
ER -